remus-pharmaceuticals-ltd

Home

Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Ltd Financials

Remus Pharmaceuticals Ltd Financial Statement

Remus Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Remus Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	63.50	45.03	24.72
Operating Expenses Annual	43.45	34.48	20.58
Operating Profit Annual	23.74	12.12	4.86
Interest Annual	0.32	0.23	0.09
Depreciation	0.90	0.48	0.15
Net Profit Annual	16.82	8.50	3.43
Tax Annual	5.71	2.91	1.18

Particulars	Mar 2024
Total Revenue Annual	63.50
Operating Expenses Annual	43.45
Operating Profit Annual	23.74
Interest Annual	0.32
Depreciation	0.90
Net Profit Annual	16.82
Tax Annual	5.71

Remus Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	3.04	1.15	0.83
Cash Flow from Operations	2.43	5.31	5.04
Cash Flow from Investing	-20.90	-15.19	-4.55
Cash Flow from Financing	39.29	11.77	-0.17
Cash Flow at the End	23.85	3.04	1.15

Particulars	Mar 2024
Cash Flow at the Beginning	3.04
Cash Flow from Operations	2.43
Cash Flow from Investing	-20.90
Cash Flow from Financing	39.29
Cash Flow at the End	23.85

Remus Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	37.39	26.92	19.66
PBIT Margin (%)	35.97	25.85	19.05
PBT Margin (%)	-76.49	-86.54	-192.20
Net PROFIT Margin (%)	26.49	18.88	13.88
Return On Networth / Equity (%)	33.24	66.10	70.58
Return On Networth /Employed (%)	41.05	68.21	92.25
Return On Assets (%)	30.20	49.83	67.30
Total Debt / Equity (X)	0.09	0.32	0.05
Asset Turnover Ratio (%)	1.14	2.64	4.85

Particulars	Mar 2024
PBDIT Margin (%)	37.39
PBIT Margin (%)	35.97
PBT Margin (%)	-76.49
Net PROFIT Margin (%)	26.49
Return On Networth / Equity (%)	33.24
Return On Networth /Employed (%)	41.05
Return On Assets (%)	30.20
Total Debt / Equity (X)	0.09
Asset Turnover Ratio (%)	1.14

Remus Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	2.29	2.54	0.31
Total Current Assets Annual	51.16	11.34	7.69
Non Current Assets Annual	46.90	23.32	8.17
Total Shareholders Funds Annual	82.06	19.14	6.58
Total Assets Annual	98.05	34.66	15.86

Particulars	Mar 2024
Fixed Assets Annual	2.29
Total Current Assets Annual	51.16
Non Current Assets Annual	46.90
Total Shareholders Funds Annual	82.06
Total Assets Annual	98.05

Remus Pharmaceuticals Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 12, 2024, Remus Pharmaceuticals Ltd has a market capitalization of 1,016.27 Cr. Value Research classifies it as a Small-Cap company.

Yes, Remus Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.02.

In FY 2023 , Remus Pharmaceuticals Ltd recorded a total revenue of approximately 63.50 Cr marking a significant milestone in the company's financial performance.

Remus Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.5% annually, respectively..

Remus Pharmaceuticals Ltd's current PE ratio is 60.42.

Remus Pharmaceuticals Ltd's ROCE averaged 46.6% from the FY ending March 2022 to 2024, with a median of 43.0%. It peaked at 69.4% in March 2022, reflecting strong capital efficiency over the period..

Remus Pharmaceuticals Ltd's latest EBIT is Rs. 22.84 Cr, surpassing the average EBIT of Rs. 13.06 Cr over the 5 years..